- HOME
- 기술정보
- 논문
논문
논문 기본정보
흰쥐에서의 신규 항암제 BR-28702-2의 체내동태
논문 개요
| 기관명 | NDSL |
|---|---|
| 저널명 | The journal of applied pharmacology : the official journal of the Korean Society of Applied Pharmacology |
| ISSN | 1225-6110, |
| ISBN |
논문저자 및 소속기관 정보
| 저자(한글) | 용철순,이신웅,전철수,채희상,신원섭,백우현 |
|---|---|
| 저자(영문) | |
| 소속기관 | |
| 소속기관(영문) | |
| 출판인 | |
| 간행물 번호 | |
| 발행연도 | 1995-01-01 |
| 초록 | The purpose of this study was to determine pharmacokinetic parameters of BR-28702-2, a new antineoplastic agent which is the conjugate of nucleotide and phospholipid, and to compare them with those of ara-C. Male rats were cannulated in the left femoral vein and received a single i.v. bolus dose of either BR-28702-2 or ara-C. BR-28702-2 was also administered i.p. and plasma samples were analyzed by reversedphase HPLC. The t $_{1}$ 2( $ beta$ )/ of ara-C(1.22 hr.) was significantly smaller than that of BR-28702-2(4.420 hr.). The absolute bioavailability of BR-28702-2 after i.p. injection was 1.125%. This lower bioavailability, together with previous reports that marked antineoplastic activity was observed when given i.p., indicates that BR-28702-2 would act as a depot system to release active moieties. Further works, therefore, need to be done to characterize active metabolites. |
| 원문URL | http://click.ndsl.kr/servlet/OpenAPIDetailView?keyValue=03553784&target=NART&cn=JAKO199511920962193 |
| 첨부파일 |
추가정보
| 과학기술표준분류 | |
|---|---|
| ICT 기술분류 | |
| DDC 분류 | |
| 주제어 (키워드) | 1- lt,TEX gt,$ beta$ lt,/TEX gt,-D-arabinofuranosylcytosine-5-diphosphate-rac-1- Omicron,-hexadecyl-2- Omicron,-palmitoyl glycerol (ara-CDP-DL-PCA),Cytosine arabinoside(ara-C), nucleotide,phospholipid,antineoplastic activity,pharmacokinetics |